Tissue and serum lipoxin A4 levels in psoriasis patients and their relation with disease severity

Background Psoriasis disease is a chronic hyperproliferative inflammatory disease, in which genetic and environmental factors have an important role, but the exact cause is yet unknown. Lipoxin A4 plays a role in improvement of psoriasis cases, it blocks the production of the proinflammatory cytokine tumor necrosis factor with increasing the production of the anti-inflammatory cytokine, c–c chemochine receptor-5 by T lymphocytes, and it reduces the perception of pain due to inflammation. Aim Detection of the expression of lipoxin A4 in the tissue and serum of psoriatic patients as compared with normal-control persons to investigate the possible role of lipoxin A4 in the psoriasis pathogenesis and its correlation with disease severity. Patients and methods The present study included 25 psoriatic patients and 25 age, sex-matched healthy controls. Four-mm punch-skin biopsy was taken from patients (psoriatic lesion) and control persons and it was kept in lysis solution for the stability of the studied parameters and it was kept frozen at –80°C till analysis of lipoxin A4 by PCR. Peripheral blood samples for detection of serum lipoxin A4 were taken. Blood samples were centrifuged and the serum was stored at –80°C and used for enzyme-linked immunosorbent assay. Results Psoriatic patients had significantly lower tissue and serum lipoxin A4 levels as compared with normal-control persons. Conclusions Lipoxin A4 could contribute to psoriasis pathogenesis through its immunomodulatory role.